Why the study?
Data deploying PFA for VT ablation in humans are scarce, and its use for VT ablation in congenital heart disease had not been reported.
Does pulsed field ablation prevent recurrent ventricular tachycardia in a patient with Ebstein's anomaly?
Population
One 33-year-old patient with Ebstein anomaly and recurrent sustained monomorphic VT
Comparison
Pulsed field ablation of VT substrate
Design
Case report
Follow-up
3 months
Authors
Loading...
PFA appears feasible for VT in Ebstein’s anomaly; hypothesis-generating and requires prospective validation before broader adoption.
Does pulsed field ablation prevent recurrent ventricular tachycardia in a patient with Ebstein's anomaly?
Pulsed field ablation may be a safe and effective treatment for recurrent ventricular tachycardia in patients with congenital heart disease such as Ebstein's anomaly, particularly when prior radiofrequency ablation has failed.
Krause et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: